Skip to content
20-F

Annual Report (Foreign)

Abivax S.A. AAVXF ABVX

0001956827-25-000010

← back to feed
Filed
Mar 24, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Dec 31, 2024 63.35M sh
Shares Diluted FY 2024 · Dec 31, 2022 19.09M sh
Operating Cash Flow FY 2024 · Dec 31, 2022 −€53.94M
Current Liabilities restated FY 2024 · Dec 31, 2022 €51.46M
Current Assets FY 2024 · Dec 31, 2022 €36.18M
Total Assets FY 2024 · Dec 31, 2022 €75.54M
Eps Diluted FY 2024 · Dec 31, 2022 −€3.18
Eps Basic FY 2024 · Dec 31, 2022 −€3.18
Rd Expense FY 2024 · Dec 31, 2022 €48.3M
Net Income FY 2024 · Dec 31, 2022 −€60.74M
Operating Income FY 2024 · Dec 31, 2022 −€64.84M
Cash And Equivalents FY 2024 · Dec 31, 2021 €60.7M
Stockholders Equity FY 2024 · Dec 31, 2021 €25.93M